Kolon Life Science Inc (102940) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kolon Life Science Inc (102940) has a cash flow conversion efficiency ratio of 0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.58 Billion ≈ $1.75 Million USD) by net assets (₩346.41 Billion ≈ $234.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Kolon Life Science Inc (102940) liquidity interval to measure how many days the company can operate on defensive assets alone.
Kolon Life Science Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Kolon Life Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kolon Life Science Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kolon Life Science Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elite Color Environmental Resources
SHE:002998
|
0.002x |
|
Shih Her Technologies
TWO:3551
|
-0.157x |
|
Hsin Kuang Steel Co Ltd
TW:2031
|
0.126x |
|
Top Bright Holding Co Ltd
TW:8499
|
0.028x |
|
Jiangsu Flag Chemical Industry Co Ltd
SHE:300575
|
0.074x |
|
Schweiter Technologies AG
SW:SWTQ
|
0.037x |
|
Bank of Marin Bancorp
NASDAQ:BMRC
|
0.032x |
|
North American Construction Group Ltd
TO:NOA
|
0.117x |
Annual Cash Flow Conversion Efficiency for Kolon Life Science Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Kolon Life Science Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Kolon Life Science Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩149.34 Billion ≈ $101.20 Million |
₩-14.08 Billion ≈ $-9.55 Million |
-0.094x | +47.78% |
| 2023-12-31 | ₩137.67 Billion ≈ $93.30 Million |
₩-24.87 Billion ≈ $-16.85 Million |
-0.181x | -45.27% |
| 2022-12-31 | ₩167.72 Billion ≈ $113.66 Million |
₩-20.85 Billion ≈ $-14.13 Million |
-0.124x | +23.64% |
| 2021-12-31 | ₩99.41 Billion ≈ $67.37 Million |
₩-16.19 Billion ≈ $-10.97 Million |
-0.163x | -29.16% |
| 2020-12-31 | ₩57.96 Billion ≈ $39.28 Million |
₩-7.31 Billion ≈ $-4.95 Million |
-0.126x | +36.89% |
| 2019-12-31 | ₩101.02 Billion ≈ $68.46 Million |
₩-20.18 Billion ≈ $-13.68 Million |
-0.200x | -555.43% |
| 2018-12-31 | ₩446.15 Billion ≈ $302.35 Million |
₩-13.60 Billion ≈ $-9.22 Million |
-0.030x | -100.45% |
| 2017-12-31 | ₩545.41 Billion ≈ $369.62 Million |
₩-8.29 Billion ≈ $-5.62 Million |
-0.015x | -114.05% |
| 2016-12-31 | ₩259.79 Billion ≈ $176.05 Million |
₩28.11 Billion ≈ $19.05 Million |
0.108x | -29.56% |
| 2015-12-31 | ₩135.44 Billion ≈ $91.79 Million |
₩20.81 Billion ≈ $14.10 Million |
0.154x | +72.96% |
| 2014-12-31 | ₩136.17 Billion ≈ $92.28 Million |
₩12.10 Billion ≈ $8.20 Million |
0.089x | -- |
About Kolon Life Science Inc
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more